Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLNN NASDAQ:DMAC NASDAQ:ELYM NASDAQ:IMRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLNNClene$7.05+8.5%$5.94$2.28▼$13.50$83.05M0.89362,655 shs270,742 shsDMACDiaMedica Therapeutics$6.36+1.6%$6.74$3.47▼$10.42$342.70M0.99205,593 shs94,978 shsELYMEliem Therapeutics$11.41+2.1%$8.10$2.35▼$11.55$339.47M-0.39486,688 shs375,352 shsIMRXImmuneering$5.14-4.5%$5.34$1.24▼$10.08$332.56M0.371.34 million shs880,540 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLNNClene0.00%-9.22%+0.31%+58.15%+146.21%DMACDiaMedica Therapeutics-0.95%-3.99%-0.63%-27.46%+57.29%ELYMEliem Therapeutics+0.45%+15.27%+32.82%+100.90%+800.81%IMRXImmuneering+3.86%+3.66%-5.61%+8.47%+320.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLNNClene$7.05+8.5%$5.94$2.28▼$13.50$83.05M0.89362,655 shs270,742 shsDMACDiaMedica Therapeutics$6.36+1.6%$6.74$3.47▼$10.42$342.70M0.99205,593 shs94,978 shsELYMEliem Therapeutics$11.41+2.1%$8.10$2.35▼$11.55$339.47M-0.39486,688 shs375,352 shsIMRXImmuneering$5.14-4.5%$5.34$1.24▼$10.08$332.56M0.371.34 million shs880,540 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLNNClene0.00%-9.22%+0.31%+58.15%+146.21%DMACDiaMedica Therapeutics-0.95%-3.99%-0.63%-27.46%+57.29%ELYMEliem Therapeutics+0.45%+15.27%+32.82%+100.90%+800.81%IMRXImmuneering+3.86%+3.66%-5.61%+8.47%+320.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLNNClene 2.71Moderate Buy$33.25371.63% UpsideDMACDiaMedica Therapeutics 2.67Moderate Buy$12.3393.92% UpsideELYMEliem Therapeutics 0.00N/AN/AN/AIMRXImmuneering 2.86Moderate Buy$16.50221.01% UpsideCurrent Analyst Ratings BreakdownLatest CLNN, DMAC, ELYM, and IMRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026CLNNClene Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/8/2026CLNNClene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/4/2026CLNNClene HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.005/4/2026CLNNClene D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.004/22/2026CLNNClene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026DMACDiaMedica Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026IMRXImmuneering Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/13/2026CLNNClene Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$48.003/12/2026CLNNClene D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.003/9/2026IMRXImmuneering Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.00(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLNNClene$200K415.25N/AN/A($1.62) per share-4.35DMACDiaMedica TherapeuticsN/AN/AN/AN/A$0.88 per shareN/AELYMEliem TherapeuticsN/AN/AN/AN/A$3.90 per shareN/AIMRXImmuneeringN/AN/AN/AN/A$3.38 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLNNClene-$26.17M-$2.60N/AN/AN/A-13,086.50%N/A-135.77%N/ADMACDiaMedica Therapeutics-$32.77M-$0.71N/AN/AN/AN/A-77.15%-69.23%N/AELYMEliem Therapeutics-$35.12M-$0.53N/AN/AN/AN/A-47.03%-45.97%N/AIMRXImmuneering-$56.03M-$1.38N/AN/AN/AN/A-43.33%-39.75%5/14/2026 (Estimated)Latest CLNN, DMAC, ELYM, and IMRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CLNNClene-$0.6367-$0.69-$0.0533-$0.69$0.05 million$0.02 million5/14/2026Q1 2026IMRXImmuneering-$0.30N/AN/AN/AN/AN/A5/6/2026Q1 2026DMACDiaMedica Therapeutics-$0.17-$0.19-$0.02-$0.19$13.50 millionN/A3/30/2026Q4 2025DMACDiaMedica Therapeutics-$0.17-$0.17N/A-$0.17$13.50 millionN/A3/12/2026Q4 2025CLNNClene-$0.74-$0.88-$0.14-$0.88$0.03 million$0.08 million3/6/2026Q4 2025IMRXImmuneering-$0.31-$0.18+$0.13-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLNNCleneN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/AELYMEliem TherapeuticsN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLNNCleneN/A0.830.83DMACDiaMedica TherapeuticsN/A9.119.11ELYMEliem TherapeuticsN/A60.4160.41IMRXImmuneeringN/A17.5017.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLNNClene23.28%DMACDiaMedica Therapeutics10.12%ELYMEliem Therapeutics69.76%IMRXImmuneering67.65%Insider OwnershipCompanyInsider OwnershipCLNNClene28.30%DMACDiaMedica Therapeutics5.00%ELYMEliem Therapeutics4.70%IMRXImmuneering22.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLNNClene10011.78 million8.45 millionNo DataDMACDiaMedica Therapeutics2053.88 million51.19 millionOptionableELYMEliem Therapeutics929.75 million28.35 millionNot OptionableIMRXImmuneering6064.70 million49.88 millionNot OptionableCLNN, DMAC, ELYM, and IMRX HeadlinesRecent News About These CompaniesImmuneering Corporation (NASDAQ:IMRX) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 12 at 2:13 AM | americanbankingnews.comWe're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash WiselyMay 6, 2026 | finance.yahoo.comImmuneering (IMRX) Expected to Announce Quarterly Earnings on MondayApril 27, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and McKesson (MCK)April 23, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Passage Bio (PASG) and Immuneering (IMRX)April 21, 2026 | theglobeandmail.comImmuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual MeetingApril 21, 2026 | globenewswire.comImmuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic ...April 21, 2026 | markets.businessinsider.comImmuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and BeyondApril 20, 2026 | globenewswire.comImmuneering (NASDAQ:IMRX) Upgraded at Wall Street ZenApril 19, 2026 | marketbeat.comImmuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by AnalystsApril 17, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Microbot Medical (MBOT), Arvinas Holding Company (ARVN) and Immuneering (IMRX)April 16, 2026 | theglobeandmail.comImmuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch NearsApril 14, 2026 | marketbeat.comImmuneering to Present at the 25th Annual Needham Virtual Healthcare ConferenceApril 6, 2026 | globenewswire.comImmuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and SurvivalMarch 17, 2026 | globenewswire.comX4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst AttentionMarch 9, 2026 | 247wallst.comImmuneering Corporation Reports 64% Overall Survival in Phase 2a Trial for First-Line Pancreatic Cancer and Outlines 2026 Development PlansMarch 6, 2026 | quiverquant.comQImmuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesMarch 6, 2026 | globenewswire.comImmuneering to Present at the Leerink Global Healthcare ConferenceMarch 2, 2026 | globenewswire.comImmuneering Corporation to Present at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFebruary 18, 2026 | quiverquant.comQImmuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFebruary 18, 2026 | globenewswire.comImmuneering (NASDAQ:IMRX) Insider Purchases $24,990.00 in StockJanuary 22, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLNN, DMAC, ELYM, and IMRX Company DescriptionsClene NASDAQ:CLNN$7.05 +0.55 (+8.46%) Closing price 04:00 PM EasternExtended Trading$6.84 -0.22 (-3.05%) As of 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.DiaMedica Therapeutics NASDAQ:DMAC$6.36 +0.10 (+1.60%) Closing price 04:00 PM EasternExtended Trading$6.36 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Eliem Therapeutics NASDAQ:ELYM$11.41 +0.24 (+2.15%) As of 05/13/2026Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.Immuneering NASDAQ:IMRX$5.14 -0.24 (-4.46%) Closing price 04:00 PM EasternExtended Trading$5.16 +0.02 (+0.29%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
